Company Quick10K Filing
Exicure
10-K 2019-12-31 Filed 2020-03-10
10-Q 2019-09-30 Filed 2019-11-07
10-Q 2019-06-30 Filed 2019-08-08
10-Q 2019-03-31 Filed 2019-05-08
10-K 2018-12-31 Filed 2019-03-08
10-Q 2018-09-30 Filed 2018-11-06
S-1 2018-09-21 Public Filing
10-Q 2018-06-30 Filed 2018-08-06
10-Q 2018-03-31 Filed 2018-05-15
10-K 2017-12-31 Filed 2018-03-09
10-Q 2017-09-30 Filed 2017-11-14
10-Q 2017-08-31 Filed 2017-09-12
10-Q 2017-05-31 Filed 2017-07-11
8-K 2020-03-30 Earnings, Regulation FD, Other Events, Exhibits
8-K 2020-03-05 Enter Agreement, Off-BS Arrangement
8-K 2020-03-03 Earnings, Exhibits
8-K 2019-12-23 Enter Agreement, Other Events, Exhibits
8-K 2019-12-11 Other Events
8-K 2019-11-14 Enter Agreement
8-K 2019-11-07 Earnings, Exhibits
8-K 2019-09-12 Other Events
8-K 2019-08-08 Earnings, Exhibits
8-K 2019-08-07 Officers, Other Events, Exhibits
8-K 2019-08-02 Enter Agreement, Other Events, Exhibits
8-K 2019-07-23 Officers, Other Events, Exhibits
8-K 2019-06-27 Regulation FD, Other Events, Exhibits
8-K 2019-06-17 Shareholder Vote
8-K 2019-05-08 Earnings, Exhibits
8-K 2019-03-08 Earnings, Exhibits
8-K 2019-03-08 Enter Agreement, Exhibits
8-K 2019-02-17 Enter Agreement, Officers
8-K 2019-02-01 Officers
8-K 2019-01-07 Earnings
8-K 2018-11-06 Earnings, Exhibits
8-K 2018-10-10 Other Events, Exhibits
8-K 2018-08-22 Enter Agreement, Sale of Shares, Regulation FD, Other Events, Exhibits
8-K 2018-08-06 Earnings, Exhibits
8-K 2018-06-19 Shareholder Vote
8-K 2018-05-24 Other Events
8-K 2018-05-15 Earnings, Exhibits
8-K 2018-04-30 Other Events, Exhibits
8-K 2018-04-16 Officers
8-K 2018-03-09 Earnings, Exhibits

Exicure Financials

XCUR Metrics, Comps, Filings

Quarterly | Annual

Business

We are a clinical-stage biotechnology company developing therapeutics for immuno-oncology, inflammatory diseases and genetic disorders based on our proprietary Spherical Nucleic Acid, or SNA, technology. SNAs are nanoscale constructs consisting of densely packed synthetic nucleic acid sequences that are radially arranged in three dimensions. We believe the design of our SNAs gives rise to distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and enable therapeutic activity outside of the liver. Since our SNAs have shown in a Phase 1 clinical trial and in preclinical studies that they can cross certain biological barriers when administered locally, we believe that they have the therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. We have demonstrated the ability to cross certain biological barriers in Phase 1 clinical trials of three therapeutic candidates, AST-008, XCUR17 and AST-005.

AST-008 is an SNA consisting of toll-like receptor 9, or TLR9, agonists designed for immuno-oncology applications. TLR9 agonists bind to and activate TLR9 receptors. We believe AST-008 may be used for immuno-oncology applications as a monotherapy or in combination with checkpoint inhibitors. Checkpoint inhibitors are therapeutics that prevent tumors from evading destruction by the immune system. We have observed that administration of AST-008 as a monotherapy can have anti-tumor activity in mouse models of colon cancer, breast cancer, lymphoma and melanoma. We have also observed that, in preclinical studies in a variety of tumor models, AST-008, applied in combination with certain checkpoint inhibitors, exhibited anti-tumor responses and survival rates that were greater than those demonstrated by checkpoint inhibitors alone. We have also demonstrated that AST-008 was active when administered subcutaneously, intratumorally or intravenously, in both prevention and established mouse tumor models. The administration of AST-008 also produced localized as well as abscopal anti-tumor activity in mouse cancer models. Additionally, administration of AST-008 in combination with certain checkpoint inhibitors conferred adaptive immunity in breast and colon cancer mouse models.

During the fourth quarter of 2018 the FDA opened the IND for AST-008 and informed the Company that our proposed Phase1b/2 trial may proceed. Early in 2019, we opened four clinical sites and began dosing and recruiting patients in that trial. This is a Phase 1b/2, open-label, multi-center trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of intratumoral AST-008 injections alone and in combination with intravenous pembrolizumab in patients with advanced solid tumors. Conditions under study are planned to include advanced or metastatic: Merkel cell carcinoma, head and neck squamous cell carcinoma, cutaneous squamous cell carcinoma and melanoma. The primary outcome measure is the safety and tolerability of AST-008 alone and in combination with pembrolizumab. Secondary outcomes include the recommended Phase 2 dose and disease assessment with RECIST 1.1.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Equity

Income Statement ($MM Quarterly)

Revenue, G Profit, Net Income

Cash Flow ($MM Quarterly)

Ops, Inv, Fin

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Luboa Group (LBAO) 228,780 311.9 87% 789 1,348 0 0 687 733 228,505
Invesco CurrencyShares Japanese Yen Trust (FXY) 228,571 29,017.4 -0% 220,131 90 0 0 -1,017 -812 -23,562,082
SpringWorks (SWTX) 227,222 6.9 -5% 348,395 11,076 0 0 -16,833 -16,833 -116,603
Success Entertainment Group (SEGN) 225,300 53% -408.0 -70% 788 696 235 124 -553 -552 225,293
Kaleido Biosciences (KLDO) 222,412 -2.4 -73% 91,212 25,172 0 0 -66,819 -65,079 153,821
Citizens Financial Services (CZFS) 219,586 0% 5.7 1% 1,475,005 1,323,327 5,197 0 18,962 34,712 199,500
Emergent Capital (EMG) 177,018 0% -5.2 -69% 85,384 121,307 35,301 0 -58,692 -33,490 175,594
Isabella Bank (ISBA) 218,480 0% 6.3 1% 1,813,684 1,601,308 4,294 0 12,126 29,281 184,149
Crimson Wine Group (CWGL) 217,967 41% 169.4 -2% 247,334 40,543 66,627 27,638 -3,816 1,332 225,647
Xerium Technologies (XRM) 217,666 10% 24.6 -3% 547,188 698,205 486,466 48,974 -16,156 30,283 743,584
Exicure (XCUR) 212,785 0% -7.2 -29% 73,806 8,854 992 0 -21,077 -20,488 147,392
Powercomm Holdings (PCC) 210,454 29% 84.1 29% 5,177 4,207 10,712 3,081 1,486 2,500 210,300
Bovie Medical (BVX) 206,243 65% -11.4 -15% 86,943 10,210 25,892 16,732 -13,330 -12,697 144,111
Bicycle Therapeutics (BCYC) 200,512 0% -5.3 -17% 116,060 20,735 2,136 0 -19,699 -19,652 104,558
Fuse Enterprises (FSNT) 200,164 86% -191.4 -95% 1,099 2 1,016 870 -1,046 -1,046 200,124
Solbright (SBRT) 195,093 -11% -4.2 -411% 12,978 107,736 3,481 -399 -53,291 -45,982 194,304
HOOKIPA Pharma (HOOK) 197,170 0% -2.3 -22% 152,037 26,280 8,324 0 -32,793 -32,034 73,160
Corvus Gold (CORVF) 170,478 -15.3 -106% 10,214 765 0 0 -10,858 -10,858 166,332
Union Bridge Holdings (UGHL) 188,095 26% -422.5 -815% 55 977 65 17 -445 -445 188,075
IDEAYA Biosciences (IDYA) 186,410 -3.7 -18% 122,331 11,925 0 0 -21,625 -21,025 77,010

Balance Sheet ($'000)2017-05-312017-08-312017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash7222,93625,76421,12416,38032,44626,26822,19617,17570,392
Accounts Receivable22523
Inventory
PP&E1,8352,1662,1932,2132,2272,2502,2532,3263,051
Assets7225,37128,05524,35419,34335,52628,75625,18420,25673,806
Accounts Payable2,3791,0499741,0451,3415008489171,110
Long-Term Debt5,4044,9994,9994,9994,9994,9994,9994,9994,999
Liabilities272813,6899,1088,0469,44110,3287,8049,0298,8658,854
Stockholders' Equity-20-2611,68218,94716,3089,90225,19820,95216,15511,39164,952
Income Statement ($'000)2017-05-312017-08-312017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Revenue002,4972,095361957625434527
Cost of Revenue
Gross Profit
R&D3,5022,8293,2753,8354,0013,3953,4334,245
SG&A18121,2702,2402,0451,9881,9192,2081,9852,228
Tax0000000000
Net Income-18-12-2,313-3,102-5,509-6,825-5,324-4,755-5,286-5,220-5,816
Cash Flow ($'000)2017-05-312017-08-312017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash Operating-11-12-14,424-5,342-4,647-4,684-4,193-4,012-4,984-5,017
Cash Investing-2000-60-5-8-54-400
Cash Financing12618,4678,3707020,264-521758,634